###### What is already known on this topic?

-   Iron deficiency is one of the most common single-nutrient deficiencies in both developing and developed countries, and peaks in prevalence in early childhood.

-   For the laboratory assessment of iron status in young children, laboratory reference intervals are not well established and high-quality decision limits based on clinical studies are not available.

###### What this study hopes to add?

-   This study presents age- and sex-specific reference intervals for haematological and biochemical tests commonly ordered by clinicians when assessing the iron status of children.

-   Clinical laboratories may consider adopting the published paediatric reference intervals and age categories, rather than using adult reference intervals.

-   Future research to develop high quality decision limits based on clinical studies of outcomes is a priority.

Introduction {#s1}
============

Laboratory tests play an important role in clinical decision making.[@R1] Clinical laboratories are required to establish or verify 'reference intervals' (previously named 'normal ranges') for all tests offered by the laboratory.[@R2] In conjunction with other health information, clinicians make diagnostic and treatment decisions based on their patients' laboratory results in the context of the accompanying reference interval. However, clinicians are often unaware of the methods used to establish laboratory reference intervals. Reference intervals are derived from apparently healthy populations and provide two limits (lower and upper limits). The International Federation of Clinical Chemistry (IFCC) established the theory of reference intervals in 1987, and the Clinical and Laboratory Standards Institute (CLSI) provides guidelines for establishing and verifying reference intervals.[@R4] These guidelines address issues of selection of the reference subjects, statistical methods including sample size requirements, approaches to grouping results according to categories such as age and sex (termed 'partitions') and approaches to the detection and removal of outliers.

Reference intervals differ from 'decision limits'. Decision limits provide one (or more) cut-points intended to distinguish individuals with disease from those without disease.[@R2] According to a recently published quality hierarchy, decision limits based on clinical outcome studies are considered the highest quality; followed by reference intervals, and cut-off values based on clinicians' opinions or published professional recommendations.[@R6] An example of a decision limit based on clinical outcome studies is HbA~1c~ for the diagnosis of diabetes.[@R6]

It has been recognised that establishing paediatric reference intervals poses specific challenges.[@R3] These challenges include the difficulties of obtaining samples from children, and the rapidly changing physiology from the newborn period to late adolescence. A recent systematic review of the current published literature examined the statistical methods used to construct paediatric reference intervals.[@R8] Of the 22 publications identified, only 7 cited and followed the CLSI guidelines.

Iron deficiency is one of the most common single-nutrient deficiencies in both developing and developed countries, peaks in prevalence between 1 and 3 years of age and is associated with poor long-term neurodevelopment which may be irreversible.[@R9] In a report on the diagnosis and prevention of iron deficiency in children under 3 years of age, the American Academy of Pediatrics (AAP) recommends universal screening for anaemia, with measurement of haemoglobin (Hb) concentration and consideration of additional tests to assess iron status, specifically serum ferritin (SF) and C-reactive protein (CRP). Although there are no established decision limits derived from clinical studies of outcomes, the AAP recommends a cut-off value for Hb of \<110 g/L and for SF of \<12 µg/L. The AAP describes other indicators of iron status including mean corpuscular volume, iron and transferrin. Few studies have examined the reference intervals for laboratory tests of iron status in young children, sample sizes have been small and age partitions wide.[@R10]

The primary objective of this study was to establish reference intervals for haematological and biochemical tests commonly ordered by clinicians to assess the iron status in young children (10 years and younger) using the CLSI guidelines. A secondary objective was to compare the lower limit of the reference interval with the AAP currently recommended cut-off value for Hb and SF in children 1--3 years of age (age of peak prevalence for iron deficiency).

Methods {#s2}
=======

Study population {#s2a}
----------------

Healthy children, from newborn to 10 years of age, were recruited during a scheduled health supervision visit with their primary care physician. Health supervision visits occur at 2 weeks, 2, 4, 6, 9, 12, 15, 18 months and then annually around the birthday of the child. Recruitment occurred between 2008 and 2016 at paediatric and family medicine primary care practices participating in a practice-based research network called TARGet Kids! ([www.targetkids.ca](www.targetkids.ca)) in Toronto, Canada. The profile of this open longitudinal cohort has been previously described, and children with and without blood samples are similar with respect to demographics and health outcomes.[@R18] Furthermore, the prevalence of iron deficiency is similar to other Canadian studies of this age group.[@R19] Exclusion criteria were: children with associated health conditions affecting growth (eg, failure to thrive, cystic fibrosis), children with any acute or chronic conditions (other than asthma and high-functioning autism), children with severe developmental delay and families who are unable to communicate in English. Parents provided informed consent and completed a questionnaire regarding the child's age and sex.

Measures obtained by the TARGet Kids! research team include haematological and biochemical tests commonly ordered by clinicians to assess the nutritional status in young children. As a direct benefit of participating in the research, clinicians are provided with results of laboratory tests to be used for clinical purposes. For this study, we analysed data on haematological and biochemical markers of iron status recommended by the AAP; specifically Hb, mean corpuscular volume, three biochemical markers of iron status (SF, iron and transferrin) and CRP. As clinicians commonly request a complete blood count, other haematological tests, including white blood cell count and platelet count, were included in this analysis.

Sample collection and analysis {#s2b}
------------------------------

The research assistants, embedded in the primary care practices, are experienced phlebotomists and collected blood samples in lavender EDTA tubes and in serum separator tubes. Blood samples were refrigerated at the practice sites and transported to the laboratory at Mount Sinai Services (MSS) the same day. MSS provides services to researchers, is accredited and complies with regulatory standards (<http://www.mountsinaiservices.com/>). At the laboratory, blood samples were analysed fresh within 4--6 hours of collection. For haematology parameters, samples were analysed on the Sysmex XN-9000 Hematology Analyzer (Japan); for chemistry analytes, samples were analysed on the Roche platform (Switzerland) (see online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The traceability chain used for SF was IS 80/602. The lower level of detection limit for CRP is 0.15 mg/L.
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###### Supplementary Table 1

Statistical analysis {#s2c}
--------------------

For our primary objective, data were analysed following CLSI C28-A3 guidelines and by choosing appropriate statistical methods based on sample size and distribution of the analytes.[@R5] Data were first visually inspected using scatter plots, histograms and probability plots. Outliers were detected and removed using outlier detection techniques described by Horn *et al*.[@R20] Data were partitioned by sex (male/female). Age partitions were selected based on epidemiological knowledge of the changing prevalence of iron deficiency and overall child growth and development. It is well established that 1--3 years is an age of peak prevalence for iron deficiency, thus we included a specific partition for this age group. Age partitions were as follows: \<1 year (infant); \>1 year to \<3 years (toddler); \>3 years to \<6 years (preschool/early school age); \>6 years to 10 years (school age). Analysis of variance (ANOVA) and pairwise comparisons between adjacent partitions were performed to determine if there was a difference on average laboratory measures across the different age partitions. In preparing the appropriate reference interval method, normality assumption, skewness as well as kurtosis were assessed for each of the laboratory measures per partition. Finally, the parametric or non-parametric method was used to estimate the reference interval as well as 90% CI around the reference intervals after excluding the outliers for each laboratory measure overall and within each partition. The parametric method was used if the normality assumption was met or the sample size in each partition was large; the non-parametric method was used if the normality assumption failed or the sample size was limited (see online [supplementary table 2](#SP1){ref-type="supplementary-material"}). All p values were two sided and for the statistical analyses, p\<0.05 indicated a significantly different result.

For our secondary objective, we further examined Hb and SF in the age partition of children 1--3 years of age, which is the age of peak prevalence for iron deficiency. Using the cut-off values recommended by the AAP (Hb \<110 g/L; SF \<12 µg/L), we determined the proportion of children misclassified using the lower limit reference interval compared with the cut-off values.

Statistical analysis was performed using SAS V.9.4 system for Windows (Copyright © 2002--2012 SAS Institute) and the R statistical software V.3.2.3 (2015. A language and environment for statistical computing, Vienna, Austria).

Results {#s3}
=======

Samples from 2305 male and 2029 female participants (ages 10 days to 10.6 years) were used to calculate age and sex-specific reference intervals for haematological and biochemical tests of iron status. Age and sex are shown in [table 1](#T1){ref-type="table"}. Scatter plots for Hb and SF are shown in [figures 1 and 2](#F1 F2){ref-type="fig"}. Not all children had blood samples analysed for all analytes, resulting in different sample sizes for each analyte. Some children contributed a blood sample to more than one age group. Age and sex-specific paediatric reference intervals are shown in [table 2](#T2){ref-type="table"}. ANOVA across age partitions showed statistically significant differences for all analytes; adjacent partition pairwise comparisons of age partitions showed statistically significant differences for all analytes except for CRP (all age comparisons) and transferrin (3\> to \<6 years compared with ≥6 to 10 years).

![Age-dependent scatter plots by sex of haemoglobin concentration (g/L). Red dots=male; blue dots=female.](bmjpo-2017-000074f01){#F1}
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###### 

Characteristics of study population---age and sex

  Variable      Statistic        Summary
  ------------- ---------------- ------------------
  Sex           N (%)            
   Male                          2305 (53.2%)
   Female                        2029 (46.8%)
  Age, months   Median (range)   36.6 (0.36--127)

###### 

Age and sex-specific reference intervals for analytes (after excluding outliers)

  Haemoglobin, g/L                                                                                                     
  --------------------------------- ------ ---------------------- ----------------------- ------ --------------------- ------------------------
   10 days to \<1 year              288    99 (97 to 100)         133 (132 to 134)        237    100 (99 to 102)       132 (130 to 133)
   \>1 to \<3 years                 815    101 (100 to 103)       133 (132 to 134)        707    102 (100 to 104)      134 (134 to 135)
   \>3 to \<6 years                 979    107 (106 to 108)       135 (134 to 136)        844    108 (107 to 109)      136 (135 to 136)
   ≥6 to 10 years                   422    111 (108 to 112)       140 (139 to 141)        355    110 (109 to 111)      140 (139 to 141)
  **Mean corpuscular volume, fL**                                                                                      
   10 days to \<1 year              275    68 (65 to 70)          86 (84 to 88)           230    72 (71 to 73)         86 (85 to 86)
   \>1 to \<3 years                 814    67 (66 to 68)          83 (82 to 83)           687    69 (68 to 70)         83 (83 to 84)
   \>3 to \<6 years                 974    73 (72 to 73)          84 (84 to 85)           844    73 (72 to 74)         86 (85 to 86)
   ≥6 to 10 years                   415    75 (75 to 76)          87 (86 to 87)           342    77 (75 to 77)         87 (86 to 88)
  **C-reactive protein, mg/L**                                                                                         
   10 days to \<1 year              296    0.09 (0.09 to 0.09)    6.10 (5.50 to 9.00)     243    0.09 (0.09 to 0.09)   4.70 (2.90 to 5.10)
   \>1 to \<3 years                 1001   0.04 (0.03 to 0.04)    3.091 (2.79 to 3.42)    896    0.09 (0.09 to 0.09)   7.30 (5.80 to 9.40)
   \>3 to \<6 years                 1195   0.043 (0.04 to 0.05)   3.00 (2.75 to 3.28)     1073   0.05 (0.05 to 0.06)   3.50 (3.18 to 3.84)
   ≥6 to 10 years                   406    0.09 (0.09 to 0.09)    3.60 (2.70 to 4.10)     346    0.09 (0.09 to 0.09)   4.90 (4.00 to 8.90)
  **Serum ferritin, µg/L**                                                                                             
   10 days to \<1 year              266    9 (9 to 10)            115 (99 to 139)         233    10 (8 to 11)          194 (157 to 271)
   \>1 to \<3 years                 909    6 (5 to 6)             70 (65 to 79)           817    7 (6 to 8)            81 (75 to 89)
   \>3 to \<6 years                 1069   12 (11 to 12)          71 (68 to 74)           949    12 (11 to 12)         74 (71 to 81)
   ≥6 to 10 years                   411    15 (13 to 15)          81 (71 to 87)           353    13 (10 to 15)         92 (83 to 109)
  **Iron, µmol/L**                                                                                                     
   10 days to \<1 year              254    3 (2 to 4)             20 (18 to 21)           186    4 (3 to 5)            19 (17 to 20)
   \>1 to \<3 years                 786    4 (4 to 4)             21 (20 to 22)           705    4 (3 to 4)            23 (21 to 23)
   \>3 to \<6 years                 947    4 (4 to 5)             25 (23 to 26)           861    4 (4 to 4)            24 (23 to 25)
   ≥6 to 10 years                   293    5 (4 to 5)             25 (24 to 27)           251    4 (3 to 5)            24 (23 to 26)
  **Transferrin, g/L**                                                                                                 
   10 days to \<1 year              248    2.01 (1.95 to 2.08)    3.49 (3.40 to 3.54)     186    1.99 (1.92 to 2.06)   3.35 (3.28 to 3.43)
   \>1 to \<3 years                 765    2.32 (2.30 to 2.37)    3.80 (3.78 to 3.94)     669    2.30 (2.25 to 2.30)   3.70 (3.68 to 3.80)
   \>3 to \<6 years                 925    2.20 (2.20 to 2.27)    3.45 (3.40 to 3.50)     841    2.28 (2.20 to 2.30)   3.40 (3.39 to 3.46)
   ≥6 to 10 years                   292    2.20 (2.17 to 2.28)    3.60 (3.40 to 3.64)     249    2.25 (2.15 to 2.35)   3.35 (3.30 to 3.42)
  **White blood cells, ×10^9^/L**                                                                                      
   10 days to \<1 year              293    6.51 (6.06 to 6.71)    17.0 (15.22 to 18.05)   236    5.81 (5.21 to 6.50)   16.02 (15.38 to 16.61)
   \>1 to \<3 years                 824    5.51 (5.14 to 5.89)    15.7 (15.1 to 16.1)     706    5.90 (5.42 to 6.00)   15.4 (14.8 to 15.9)
   \>3 to \<6 years                 988    4.59 (4.39 to 4.76)    12.9 (12.42 to 13.79)   859    4.70 (4.31 to 4.86)   12.7 (12.4 to 13.5)
   ≥6 to 10 years                   420    4.47 (3.94 to 4.64)    12.0 (11.3 to 12.4)     351    4.47 (4.17 to 4.81)   12.7 (11.8 to 13.2)
  **Platelets, ×10^9^/L**                                                                                              
   10 days to \<1 year              281    262 (239 to 271)       598 (559 to 621)        228    237 (221 to 253)      573 (557 to 589)
   \>1 to \<3 years                 816    200 (191 to 209)       513 (496 to 527)        706    213 (190 to 224)      530 (518 to 545)
   \>3 to \<6 years                 988    195 (184 to 204)       446 (441 to 465)        843    208 (201 to 214)      439 (432 to 443)
   ≥6 to 10 years                   421    202 (190 to 210)       421 (414 to 435)        347    197 (184 to 202)      399 (389 to 442)

For both Hb and SF in children 1--3 years of age, the lower limit of the reference interval was lower than the currently recommended AAP cut-off value. For Hb, the lower limit of the reference interval was 101 g/L (male) and 102 g/L (female), whereas the currently recommended AAP cut-off value is 110 g/L; the proportion misclassified (underestimated) was 10.78% for men and 9.76% for women. For SF, the lower limit of the reference interval was 6 µg/L (male) and 7 µg/L (female), whereas the currently recommended AAP cut-off value is 12 µg/L; the proportion misclassified (underestimated) was 10.19% for men and 10.97% for women.

Discussion {#s4}
==========

We have established age and sex-specific reference intervals for several haematological and biochemical tests commonly ordered by clinicians when assessing the iron status of children. Age partitions showed statistically significant differences for most analytes, suggesting that laboratories should use these age categories. Furthermore, we found that approximately 10% of children 1--3 years of age would be misclassified as having healthy iron status (no disease) according to measures of Hb and SF, if the lower limit of the reference intervals was used rather than the cut-off values currently recommended by the AAP.

In recognition of the critical gaps in paediatric reference intervals, the IFCC Task Force on Paediatric Laboratory Medicine launched an initiative to coordinate international efforts to fill this gap, representing groups from several countries.[@R21] One group, the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER), has published several analyses that include reference intervals for several analytes relevant to the assessment of iron status in young children (see [table 3](#T3){ref-type="table"}); reference intervals are also accessible on their database website.[@R10] [@R22] However, data from CALIPER remain limited due to small sample sizes, especially for very young children, when iron deficiency peaks in prevalence. For example, Bailey *et al* presented reference intervals for SF based on 126 children 1--5 years of age.[@R12] Previous publications on the prevalence of iron deficiency in young children used data from the nationally representative US National Health and Nutrition Examination Survey (NHANES). These included a large number of laboratory tests for Hb, SF and other biochemical analytes.[@R23] However, NHANES did not establish reference intervals according to the CLSI guidelines.

###### 

CALIPER published reference intervals for several analytes relevant to the assessment of iron status in children

  Analyte                 Unit           Age range         Reference interval   Sample size, n   Reagent manufacturer   Study source   Reference
  ----------------------- -------------- ----------------- -------------------- ---------------- ---------------------- -------------- -----------
  hsCRP                   mg/L           0 to \<14 days    0.3--6.1             139              Abbott                 CALIPER        [@R10]
  15 days to \<15 years   0.1--1.0       653                                                                                           
  Serum ferritin          µg/L           0 to \<15 days    39.8--539.9          56               Beckman                CALIPER        [@R15]
  15 days to \<6 months   15.3--374.6    49                                                                                            
  6 months to \<1 year    13.3--191.9    44                                                                                            
  1 to \<16 years         10.3--55.8     424                                                                                           
  3--5 years              10.7--85.2     400               Ortho                CHMS             [@R14]                                
  Male 6--16 years        16.2--106.7    680                                                                                           
  Female 6--24 years      9.6--81.9      790                                                                                           
  4 to \<15 days          99.6--717.0    127               Abbott               CALIPER          [@R12]                                
  15 days to \<6 months   14.0--647.2    172                                                                                           
  6 months to \<1 year    8.4--181.9     140                                                                                           
  1 to \<5 years          5.3--99.9      126                                                                                           
  5 to \<14 years         13.7--78.8     497                                                                                           
  Haemoglobin             g/L            3--5 years        113.5--143.1         420              Beckman                CHMS           [@R13]
  6--8 years              114.7--143.0   670                                                                                           
  9--10 years             118.4--146.9   540                                                                                           
  Iron                    µmol/L         0 to \<14 years   2.8--22.9            588              Abbott                 CALIPER        [@R10]
  MCV                     fL             3--5 years        77.2--89.5           410              Beckman                CHMS           [@R12]
  6--11 years             77.8--91.1     1460                                                                                          
  Platelets               10^9^/L        3--5 years        187.4--444.6         420              Beckman                CHMS           [@R13]
  6--9 years              186.7--400.4   910                                                                                           
  Transferrin             g/L            0 to \<9 weeks    1.04--2.24           188              Abbott                 CALIPER        [@R10]
  9 weeks to \<1 year     1.07--3.24     104                                                                                           
  1 to \<19 years         2.20--3.37     878                                                                                           

Reference values are applicable to both sexes, unless specified otherwise.

CALIPER, Canadian Laboratory Initiative on Pediatric Reference Intervals; CHMS, Canadian Health Measures Survey; hsCRP, high-sensitivity C-reactive protein; MCV, mean corpuscular volume.

Given the challenges of developing reference intervals, it is difficult for each laboratory to develop their own reference intervals for children. As a result, clinicians are often provided with reference intervals for adults only which may lead to substantial misclassification, and possible overdiagnosis or underdiagnosis. Several prerequisites have been described in order for clinical laboratories to adopt common reference intervals.[@R3] These include the following: the population served by the clinical laboratory is similar to that from which the reference interval was developed; the clinical laboratory uses methods that the manufacturers certify produce results that are traceable to the reference measurement system for a specific analyte; precision of the methods is within acceptable targets. It is also recommended that the clinical laboratory validate the reference interval in a small sample of their own population.[@R3]

Reference intervals have inherent limitations in their application to clinical decision making. By their nature, reference intervals describe the characteristics of the referent population, which, while assumed to be healthy, may include asymptomatic individuals. Decision limits provide clinicians with the dichotomous information (disease/no disease) they seek for clinical decision making. In our study, we found wide reference intervals for SF, for example, which suggests that many children with asymptomatic iron deficiency were included in the referent population. Therefore, reference intervals may not adequately inform clinical decision making for the laboratory assessment of iron status in young children. Laboratories may also provide decision limits when available and cut-off values from published recommendations from professional organisations.[@R6]

Strengths of our study include a large sample of healthy children recruited from community settings during a health supervision visit with their primary care physician, and adherence to the CLSI guidelines. For the young age group at highest risk for iron deficiency (1--3 years), our sample size is substantially larger than previously published reference intervals.

Our study was limited to young children under 10 years of age. To fill the gaps in paediatric reference intervals, other initiatives, such as CALIPER, have large sample sizes for children older than 10 years. Furthermore, we have not addressed cut-off values for children 3--10 years of age.

For our secondary objective, our study findings are limited by the low quality of evidence used to establish the currently recommended AAP cut-off value, especially for SF. The currently recommended cut-off value of 12 µg/L for SF is not based on a clinical outcome (as required for a high-quality decision limit), but rather based on the fifth percentile of the distribution of SF in a population presumed to be healthy.[@R23] In a recent analysis examining the relationship between Hb and SF, we identified a SF value of 23.7 µg/L corresponding to the level at which Hb concentration was maximised.[@R28] If the true decision limit for SF is indeed as high as 23.7 µg/L (rather than the currently recommended cut-off value of 12 µg/L), the proportion of children misclassified using the lower limit of the reference interval would be substantially higher.

Conclusion {#s5}
==========

We have established reference intervals for haematological and biochemical tests commonly ordered by clinicians to assess the iron status in young children under 10 years of age using the CLSI guidelines. As clinical laboratories are required to provide reference intervals for all tests offered, they may consider adopting published paediatric reference intervals. We have described the methodological approaches to establishing reference intervals and decision limits to better inform clinicians of their benefits and limitations as applied to clinical decision making. In the absence of decision limits based on clinical studies of outcomes (highest quality of evidence), we have described the currently recommended cut-off values for Hb and SF in the assessment of children 1--3 years of age and have identified the potential for misclassification when using reference intervals alone. Future research should focus on establishing decision limits for the laboratory assessment of iron status based on clinical outcomes.
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